顽固性高血压的器械治疗:抑制交感神经活性
摘要
世界范围内约34%的成人患有高血压[1],高血压已成为主要致死原因,占死亡原因的13%[2]。高血压的治疗主要包括生活方式的改善和药物治疗。然而,许多患者在接受治疗后血压仍未得到良好的控制。
出处
《上海医学》
CAS
CSCD
北大核心
2014年第7期554-558,共5页
Shanghai Medical Journal
参考文献30
-
1VERLOOP W L, VOSKUIL M, DOEVENDANS P A. Renal denervation: a new treatment option in resistant arterial hypertension[J]. Neth Heart J, 2013, 21(2): 95-98.
-
2CASTRO TORRES Y, KATHOLI R E. Renal denervation for treating resistant hypertension: current evidence and future insights from a global perspective[J]. Int J Hyper- tens, 2013, 2013:513214.
-
3CALHOUN D A, JONES D, TEXTOR S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research[J]. Hypertension, 2008, 51(6): 1403-1419.
-
4PERSELL S D. Prevalence of resistant hypertension in the United States, 2003-2008[J]. Hypertension, 2011, 57(6): 1076-1080.
-
5HERING D, NARKIEWICZ K. Sympathetic nervous system and arterial hypertension: new perspectives, new data[J]. KardiolPol, 2013, 71(5): 441-446.
-
6DIBONA G F. The sympathetic nervous system and hyper- tension= recent developments[J]. Hypertension, 2004, 43 (2) : 147-150.
-
7LOHMEIER T E, HILDEBRANDT D A, WARREN S, et al. Recent insights into the interactions between the barore- flex and the kidneys in hypertension[J]. Am J Physiol Regul Integr Comp Physiol, 2005, 288(4): R828-R836.
-
8SCHMIEDER R E, REDON J, GRASSI G, et al. ESH position paper: renal denervation--an interventional therapy of resistant hypertension[J].J Hypertens, 2012, 30 (5) 837-841.
-
9Symplicity HTN-1 Investigators. Catheter-based renal sym- pathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months[J]. Hyperten- sion, 2011, 57(5): 911-917.
-
10KRUM H, SOBOTKA P, MAHFOUD F, et al. Device- based antihypertensive therapy: therapeutic modulation of the autonomic nervous system[J]. Circulation, 2011, 123(2) : 209-215.
二级参考文献13
-
1Calhoun DA, Jones D, Textor S, et al. Resistant hypertension:diagnosis, evaluation and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 2008, 51 : 1403-1419.
-
2Krum H, Sobotka P, Mahfoud F, et al. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation, 2011,123 : 209-221.
-
3Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof -of -principle cohort study. Lancet, 2009,373 : 1275-1281.
-
4Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med, 2009, 361 : 932-934.
-
5Symplicity HTN-1 investigators. Catheter-based renal sympathetic denervation for resistant hyptersion: durability of blood pressure reduction out to 24 months. Hypertension, 2011,57:911-917.
-
6Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension ( The Symplicity HTN-2 Trial) : a randomised controlled trial. Lancet, 2010,376 : 1903-1909.
-
7Prochnau D, Lauten A, Busch M, et al. Catheter-based radiofrequency ablation therapy of the renal sympathetic-nerve system for drug resistant hypertension in a patient with end-stage renal disease. Int J Cardiol,2012,154 : e29-30.
-
8Ukena C, Mahfoud F, Kindermann I, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol, 2011,58: 1176- 1182.
-
9Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med, 1999, 130: 461-470.
-
10Schlaich MP, Lambert E, Kaye DM, et al. Sympathetic augmentation in hypertension: role of nerve firing, norepinephrine reuptake, and angiotensin neuromodulation. Hypertension, 2004, 43 : 169-175.
共引文献15
-
1张晓敏(综述),汤日宁(审校),刘必成(审校).经皮经导管射频消融去肾交感神经术在难治性高血压中的应用[J].中华高血压杂志,2013,21(5):424-427.
-
2李莹,徐克雷.高血压治疗的研究进展与展望[J].实用心脑肺血管病杂志,2013,21(8):1-4. 被引量:20
-
3刘焱,董烨.经导管射频消融肾交感神经术治疗难治性高血压的护理[J].护士进修杂志,2013,28(19):1752-1754. 被引量:6
-
4蒋雄京,董徽.经皮经导管去肾神经术治疗难治性高血压的临床规范[J].心血管病学进展,2013,34(6):719-722.
-
5卢成志,张瑾.经导管去肾交感神经术——当前各种技术的优劣比较[J].心血管病学进展,2013,34(6):722-725. 被引量:2
-
6蒋雄京,董徽.经皮经导管去肾神经术治疗难治性高血压的临床规范[J].临床内科杂志,2014,31(1):10-12.
-
7张博雅.经皮经导管射频消融去肾交感神经术治疗难治性高血压临床研究[J].中国实用神经疾病杂志,2014,17(7):3-5. 被引量:1
-
8李晓兰.宫颈周围支持韧带内交感神经分布探讨[J].中国实用神经疾病杂志,2014,17(10):92-93.
-
9窦俊安.高血压治疗策略新进展[J].中国城乡企业卫生,2014,29(2):21-23.
-
10易欣,蒋丁胜,李晓艳,郭毅,蒋学俊.肾去交感神经术治疗难治性高血压疗效的Meta分析[J].中华全科医师杂志,2014,0(9):750-755. 被引量:1
-
1蔡巍,林福明,朱英琪.心率变异与高血压病的关系[J].中国康复医学杂志,1997,12(6):266-267.
-
2张朝辉,王凤.美托洛尔治疗心血管疾病研究进展[J].中国基层医药,2015,22(10):1586-1590. 被引量:7
-
3王恺皞,蒋雄京.顽固性高血压的器械治疗[J].心血管病学进展,2016,37(2):112-117. 被引量:1
-
4β受体阻滞剂不应列为一线降压药物[J].中华老年心脑血管病杂志,2011,13(5):428-428.
-
5张月军,吾柏铭,洪小苏,余荣水,陈建昌,韩婷婷,郭爱红,章惠莲.氯沙坦治疗高血压的疗效及对心率变异性影响的研究[J].高血压杂志,2001,9(3):216-218. 被引量:5
-
6于丽娟,王一尘.心力衰竭时交感神经活性的改变[J].心功能杂志,1997,9(3):154-156. 被引量:1
-
7薛辉.酗酒致心房颤动1例[J].山西职工医学院学报,1999,9(4):11-11.
-
8Sue Hughes.β受体阻断剂治疗高血压的时代结束了?[J].世界核心医学期刊文摘(心脏病学分册),2005,0(12):13-14.
-
9秦俊,张启谦,吴寿洲,宋毅.胰岛素抵抗与高血压关系[J].公共卫生与预防医学,2000,13(S1):143-143. 被引量:1
-
10吴立荣.慢性心力衰竭的病因学演变[J].医学与哲学(B),2013,34(6):14-15. 被引量:6